Gelfand J. Administration of psoriasis throughout the COVID-19 pandemic. Offered at: AAD VMX 2021; April 23-25, 2021 (Digital).
Gelfand stories consulting for Bristol Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Lilly (DMC), Janssen Biologics, Novartis Corp, UCB (DSMB) and receiving honoraria; receiving analysis grants (to the Trustees of the College of Pennsylvania) from AbbVie, Boehringer Ingelheim, Janssen, Novartis Corp, Amgen, and Pfizer Inc.; being deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology; and being a member of the board of administrators for the Worldwide Psoriasis Council, receiving no honoraria.
On this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology on the College of Pennsylvania Perelman College of Medication, spoke with Healio about COVID-19 therapy choices out there to sufferers with psoriasis.
Gelfand mentioned these therapies and different concerns for managing COVID-19 in sufferers with psoriasis throughout a presentation at AAD VMX 2021.
He defined that the Nationwide Psoriasis Basis’s COVID-19 Taskforce requires physicians who deal with COVID-19 in sufferers with psoriasis to make use of evidence-based suggestions for therapies.
“What my colleagues ought to know is that there’s been over 440 therapies reported to deal with and treatment COVID-19 within the literature,” Gelfand mentioned, including that “rigorous, placebo-controlled trials” are wanted to check the effectiveness of those therapies in COVID-19.
He mentioned therapies which have been proven to be helpful in sure sufferers with COVID-19, together with Regeneron’s monoclonal antibody cocktail amongst sufferers at excessive danger for extreme illness who’re early in illness development, and dexamethasone, remdesivir, baracitinib and tocilizumab amongst sufferers hospitalized with COVID-19.
Gelfand careworn that whereas there may be “numerous optimism for our means to deal with psoriasis throughout the pandemic,” extra work is required in public well being efforts addressing COVID-19.
“Overcoming public indifference and reluctance to vaccines is a key subsequent step to transferring issues ahead to a safer world for all of us,” he mentioned.